Axsome v. Hetero: 9-Patent Solriamfetol Infringement Action Consolidated in NJ
Axsome Malta and Axsome Therapeutics brought a nine-patent infringement action against Hetero USA and Hetero Labs in the District of New Jersey, asserting a broad portfolio covering Sunosi® solriamfetol oral tablets at both 75 mg and 150 mg doses. Within 64 days of filing, the case was consolidated with seven related actions into a single coordinated proceeding — a pattern typical of multi-wave ANDA litigation.
Nine-patent ANDA assault on Sunosi® pulled into coordinated NJ proceeding
On 19 March 2024, Axsome Malta, Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-03999 in the District of New Jersey against Hetero USA, Inc., Hetero Labs, Ltd., and Hetero Labs Limited. The complaint asserted nine United States patents — US11839598B2, US11865098B1, US11872204B1, US11850226B2, US11857528B1, US11872203B1, US11839599B2, US11850228B2, and US11850227B2 — all directed to solriamfetol formulations, protecting the branded wakefulness-promoting product Sunosi® at oral tablet doses of 75 mg and 150 mg base equivalents.
The case was not resolved on the merits in this docket. On 22 May 2024 — just 64 days after filing — the court entered an order consolidating this action with seven related cases (Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-4002, and 24-4608) into a single Consolidated Action for all purposes, including discovery, case management, and trial. Consolidation means the substantive patent disputes will be litigated together, preserving judicial resources and ensuring consistent rulings across all Hetero-related Sunosi® challenges.
The 64-day interval from filing to consolidation order is consistent with the court acting swiftly to manage a cluster of near-simultaneous ANDA filings by the same generic challenger. The volume and density of patents asserted — nine in a single action — suggests Axsome pursued a broad defensive posture, likely timed to 45-day Hatch-Waxman statutory windows. The public record is silent on whether any specific claims have been narrowed, contested, or whether any licensing discussions are underway within the consolidated proceeding.
Filing to Case Consolidated in 64 days
64-day consolidation — significantly faster than average ANDA case resolution
Case consolidated: what the court order means for both parties
Consolidation merges cases — not a merits ruling
Consolidation under Federal Rule of Civil Procedure 42(a) combines multiple actions sharing common questions of law or fact into one proceeding. Here, eight related Hetero-Axsome ANDA actions were merged for discovery, case management, and trial. No patents have been found valid or invalid, and no infringement determination has been made. The substantive dispute is very much alive — it is simply being fought on a unified front.
Procedural — no merits decidedAxsome retains all nine patents and full enforcement rights
Consolidation does not weaken Axsome’s position. All nine asserted patents remain in force and in suit. By having discovery and trial conducted once across all related actions, Axsome avoids inconsistent rulings and reduces the risk of a generic prevailing on a technicality in a standalone case. The consolidated structure also typically preserves the 30-month Hatch-Waxman stay, keeping Hetero’s ANDA approval at bay pending final judgment.
Patents intact — litigation continuesHetero faces a unified, resource-intensive multi-patent battle
For Hetero USA and Hetero Labs, consolidation means facing nine patents and multiple related actions under a single coordinated schedule, increasing litigation complexity and cost. While Hetero retains all invalidity and non-infringement defenses, the consolidated structure typically favors the patent holder by concentrating Axsome’s enforcement leverage. Hetero’s path to generic market entry for solriamfetol tablets remains blocked until the consolidated action is resolved.
Market entry deferredSunosi® exclusivity window defended by a nine-patent thicket
The breadth of the asserted portfolio — nine patents across multiple application numbers — signals a layered IP strategy consistent with life-cycle management of a branded CNS wakefulness agent. Competing generic manufacturers watching this consolidated action should note that Axsome has constructed overlapping claims across formulation, dosage, and potentially method-of-use dimensions, raising the invalidity hurdle for any challenger. A settlement or consent judgment in the consolidated action would set market-entry timing for all Hetero solriamfetol products simultaneously.
Layered patent thicket — high challenge barFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical IP holding and commercial entity — holder of US11839598B2 and 8 further solriamfetol patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturer and its US subsidiary seeking ANDA approval for solriamfetol tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kaan Ekiner | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Cozen O’connor PC | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s consolidation order is purely procedural — it reflects judicial efficiency in managing a cluster of parallel ANDA infringement actions, not a substantive determination on validity or infringement. The order’s scope (‘for all purposes, including discovery, case management, and trial’) means every future ruling, including claim construction and any summary judgment, will bind all consolidated defendants simultaneously. Neither party has gained or lost on the merits; the order effectively resets the litigation clock under a unified schedule.
US11839598B2 — Solriamfetol formulations for wakefulness and CNS disorders
The nine asserted patents — anchored by US11839598B2 and spanning US11865098B1, US11872204B1, US11850226B2, US11857528B1, US11872203B1, US11839599B2, US11850228B2, and US11850227B2 — collectively protect solriamfetol, a dopamine and norepinephrine reuptake inhibitor approved under the brand name Sunosi® for treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The application numbers cluster in the US18/194xxx and US18/323xxx families, suggesting a coordinated continuation and divisional strategy filed in the early 2020s to build overlapping protection around the commercial product.
For the CNS pharmaceutical sector, a nine-patent Orange Book listing against a single generic creates a formidable enforcement moat. The portfolio’s breadth — spanning multiple application families — indicates Axsome has sought to protect not only the core solriamfetol molecule but also specific formulation parameters, dosage strengths, and potentially methods of use. Competitors developing solriamfetol generics or pursuing related dopamine/norepinephrine reuptake inhibitor therapeutics should treat this portfolio as a high-priority FTO target, particularly given the likelihood of additional pending continuations from the same priority chains.
Should you run an FTO against the Axsome solriamfetol patent portfolio?
Any pharmaceutical company, contract development organization, or generic manufacturer with active programs in wakefulness-promoting agents, dopamine/norepinephrine reuptake inhibitors, or excessive daytime sleepiness therapeutics should treat the nine-patent Axsome solriamfetol portfolio as a mandatory FTO priority. The consolidated NJ action confirms these patents are being actively enforced, and the continuation filing strategy suggests additional family members may still be pending — creating moving-target risk for product development teams.
PatSnap Eureka’s FTO Search Agent can map the full Axsome solriamfetol patent family — including pending continuations, divisionals, and international counterparts — against your specific formulation parameters and dosage configurations. Eureka’s claim chart automation and prior art identification tools accelerate the FTO process from weeks to days, giving your R&D and regulatory teams the freedom-to-operate clarity needed before committing to ANDA timelines or manufacturing scale-up.
Run a freedom-to-operate analysis on US11839598B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA solriamfetol and CNS formulation patent cases in NJ District Court
Cases involving multi-patent ANDA enforcement actions for CNS wakefulness agents in the District of New Jersey, including related Axsome v. Hetero consolidated dockets.
What this case signals for the CNS and ANDA patent litigation landscape
A nine-patent assertion against a single generic challenger in 64 days illustrates modern Hatch-Waxman portfolio enforcement tactics.
Nine-patent filings in ANDA cases are deliberate portfolio strategy, not excess
Axsome’s decision to list nine patents against Hetero’s ANDA reflects a well-established pharmaceutical IP tactic: exhausting the generic challenger’s invalidity budget and forcing settlement on brand-favorable terms. Each additional patent requires Hetero to mount a separate invalidity or non-infringement argument, compounding litigation costs. Companies monitoring solriamfetol or adjacent CNS stimulant ANDA landscapes should map the full Orange Book listing, not just the lead patent.
Rapid consolidation signals active docket management in NJ for pharma ANDA clusters
The District of New Jersey consolidated eight related Hetero-Axsome cases within 64 days of the last filing — consistent with the court’s well-documented efficiency in managing large ANDA dockets. IP teams tracking generic entry timelines for Sunosi® should monitor the consolidated docket (lead case 23-20354) rather than individual case numbers, as all scheduling orders, claim construction, and trial dates will issue from that single proceeding going forward.
Axsome v Hetero — key questions answered
Axsome Malta and Axsome Therapeutics asserted nine patents: US11839598B2, US11865098B1, US11872204B1, US11850226B2, US11857528B1, US11872203B1, US11839599B2, US11850228B2, and US11850227B2. All nine cover solriamfetol formulations protecting the branded product Sunosi® at 75 mg and 150 mg oral tablet doses.
The case was not settled. It was closed after 64 days because the District of New Jersey consolidated it with seven related Axsome v. Hetero actions (Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-4002, 24-4608) into a single Consolidated Action. No merits ruling was made; litigation continues under the lead consolidated docket.
Consolidation typically preserves the 30-month Hatch-Waxman stay triggered by the infringement action, meaning Hetero’s ANDA for solriamfetol tablets remains blocked from FDA approval pending final judgment in the Consolidated Action. Hetero must now litigate validity and non-infringement across all nine patents in a single unified proceeding.
The District of New Jersey is managing the consolidated proceedings. The lead case in the Consolidated Action is No. 23-20354. All discovery, case management orders, claim construction hearings, and trial proceedings will be conducted under that docket number.
The public record does not confirm pending applications, but the clustering of asserted patents in the US18/194xxx and US18/323xxx application families suggests a continuation and divisional filing strategy. It is consistent with industry practice that additional family members from the same priority chains may be pending and could be asserted against future ANDA filers. An FTO search across the full Axsome solriamfetol patent family is advisable for any potential generic entrant.
PatSnap Eureka searches patents and litigation data to answer instantly.